MSCs for Induction of Solid Organ Allograft Acceptance

  • Marc Dahlke
  • Philipp Renner
  • Elke Eggenhofer
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)


Over the past four decades, the transplantation of solid organs (liver, kidney, heart, pancreas, and lung) has become standard clinical therapy. Despite its overall success, the shortage of donor organs and the need for lifelong immunosuppression continue to pose major challenges that need to be addressed. This chapter summarizes the preclinical efforts undertaken to investigate the potential use of mesenchymal stromal cells in the field of solid organ transplantation and presents insights into the concepts of ongoing early clinical studies.


Graft Survival Mesenchymal Stromal Cell Solid Organ Transplantation Allograft Survival Multipotent Adult Progenitor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371(9624):1579–1586PubMedCrossRefGoogle Scholar
  2. 2.
    Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J et al (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21(8):1733–1738PubMedCrossRefGoogle Scholar
  3. 3.
    Salem HK, Thiemermann C (2010) Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28(3):585–596PubMedGoogle Scholar
  4. 4.
    Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW et al (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut 59(12):1662–1669PubMedCrossRefGoogle Scholar
  5. 5.
    Ingulli E (2010) Mechanism of cellular rejection in transplantation. Pediatr Nephrol 25(1):61–74PubMedCrossRefGoogle Scholar
  6. 6.
    Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10):3838–3843PubMedCrossRefGoogle Scholar
  7. 7.
    Rasmusson I, Ringden O, Sundberg B, Le Blanc K (2005) Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 305(1):33–41PubMedCrossRefGoogle Scholar
  8. 8.
    Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1):42–48PubMedCrossRefGoogle Scholar
  9. 9.
    Casiraghi F, Noris M, Remuzzi G (2010) Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Curr Opin Organ Transplant 15(6):731–737CrossRefGoogle Scholar
  10. 10.
    Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2(2):141–150PubMedCrossRefGoogle Scholar
  11. 11.
    Renner P, Eggenhofer E, Rosenauer A, Popp FC, Steinmann JF, Slowik P et al (2009) Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 41(6):2607–2611PubMedCrossRefGoogle Scholar
  12. 12.
    Hoogduijn MJ, Crop MJ, Korevaar SS, Peeters AM, Eijken M, Maat LP et al (2008) Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation 86(9):1283–1291PubMedCrossRefGoogle Scholar
  13. 13.
    Eggenhofer E, Renner P, Soeder Y, Popp FC, Hoogduijn MJ, Geissler EK et al (2011) Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 25(2–3):141–147PubMedCrossRefGoogle Scholar
  14. 14.
    Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H et al (2008) Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 20(1–2):55–60PubMedCrossRefGoogle Scholar
  15. 15.
    Liu W, Li XC (2010) An overview on non-T cell pathways in transplant rejection and tolerance. Curr Opin Organ Transplant 15(4):422–426PubMedCrossRefGoogle Scholar
  16. 16.
    Bartholomew A, Polchert D, Szilagyi E, Douglas GW, Kenyon N (2009) Mesenchymal stem cells in the induction of transplantation tolerance. Transplantation 87(9 Suppl):S55–S57PubMedCrossRefGoogle Scholar
  17. 17.
    English K, French A, Wood KJ (2010) Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 7(4):431–442PubMedCrossRefGoogle Scholar
  18. 18.
    Pilat N, Sayegh MH, Wekerle T (2011) Costimulatory pathways in transplantation. Semin Immunol 23(4):293–303PubMedCrossRefGoogle Scholar
  19. 19.
    Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, Lapini I et al (2008) Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 300(3):115–124PubMedCrossRefGoogle Scholar
  20. 20.
    Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK et al (2006) Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81(11):1589–1595PubMedCrossRefGoogle Scholar
  21. 21.
    Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D et al (2008) Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 181(6):3933–3946PubMedGoogle Scholar
  22. 22.
    Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W et al (2009) Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 9(8):1760–1772PubMedCrossRefGoogle Scholar
  23. 23.
    Dahlke MH, Hoogduijn M, Eggenhofer E, Popp FC, Renner P, Slowik P et al (2009) Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 88(5):614–619PubMedCrossRefGoogle Scholar
  24. 24.
    Hoogduijn MJ, Popp FC, Grohnert A, Crop MJ, van Rhijn M, Rowshani AT et al (2010) Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 90(2):124–126PubMedCrossRefGoogle Scholar
  25. 25.
    Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA et al (2011) Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 6(2):412–422PubMedCrossRefGoogle Scholar
  26. 26.
    Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S et al (2012) Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307(11):1169–1177PubMedCrossRefGoogle Scholar
  27. 27.
    Roemeling-van Rhijn M, Weimar W, Hoogduijn MJ (2012) Mesenchymal stem cells: application for solid-organ transplantation. Curr Opin Organ Transplant 17(1):55–62PubMedCrossRefGoogle Scholar
  28. 28.
    Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V et al (2011) Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation – a phase I study (MISOT-I). J Transl Med 9:124PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Medical Center RegensburgRegensburgGermany

Personalised recommendations